CD8A and cancer: Additionally, while our results suggest Nrp1 may not represent a viable target for manipulation of self-reactive CD8+ T cells during cancer immunotherapy, Nrp1 could represent a useful target in other scenarios, such as autoimmunity [20], [43], or as a potential biomarker to help identify autoreactive T cells in patients.